Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640105 | 0.88 | IDO1 (0.39) | IDO1USP14 | |
| SCHEMBL7264258 | 0.85 | IDO1 (0.50) | IDO1USP14 | |
| SCHEMBL22436602 | 0.85 | IDO1 (0.36) | IDO1 | |
| SCHEMBL16410320 | 0.84 | IDO1 (0.36) | IDO1USP14 | |
| SCHEMBL3640129 | 0.83 | IDO1 (0.40) | IDO1USP14 | |
| SCHEMBL29834155 | 0.81 | BACE1 (0.33) | — | |
| SCHEMBL22436459 | 0.81 | BACE1 (0.33) | — | |
| SCHEMBL5871245 | 0.80 | CYP4F2 (0.43) | IDO1 | |
| SCHEMBL5872262 | 0.80 | TKT (0.30) | — | |
| SCHEMBL2876790 | 0.79 | CA2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | IDO1 1024/4885USP14 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.